Sanofi (SNY) Tops Q1 EPS by EUR0.20

Sanofi (NASDAQ: SNY) reported Q1 EPS of EUR1.63, EUR0.20 better than the analyst estimate of EUR1.43. Revenue for the quarter came in at EUR8.97 billion versus the consensus estimate of EUR8.83 billion.

Full-year 2020 business EPS(2) guidance affirmed:

• Sanofi continues to expect 2020 business EPS(2) to grow around 5%(3) at CER, barring unforeseen major adverse events. Sanofi expects the favorable first-quarter COVID-19 impact on sales and business EPS to be mainly offset during the second quarter. Applying average April 2020 exchange rates, the currency impact on 2020 business EPS is estimated to be between -1% to -2%

For earnings history and earnings-related data on Sanofi (SNY) click here.

You May Also Be Interested In

• Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
• Sanofi (SNY) call put ratio 8.4 calls to 1 put with a focus on July 45 calls
• Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins